Sandoz Launches Generic Brimonidine Tartrate/Timolol Maleate Eyedrop in US for Patients with Ocular Hypertension

Sandoz Launches Generic Brimonidine Tartrate/Timolol Maleate Eyedrop in US for Patients with Ocular Hypertension

April 14, 2022 Off By Author

Sandoz has announced the US launch of its generic combination eyedrop brimonidine tartrate/timolol maleate ophthalmic solution 0.2%/0.5%, an AB-rated generic equivalent to AbbVie’s COMBIGAN, to lower eye pressure in patients with ocular hypertension (high eye pressure). This prescription eyedrop is immediately available to patients via retail pharmacies.

“Fixed combinations of medicines to treat ocular hypertension can offer patients enhanced convenience, improved adherence, reduced exposure to preservatives, and cost savings,” said Keren Haruvi, President, Sandoz Inc. “We developed this important generic eye treatment in-house to expand patient access to high-quality, more affordable eye care for millions of US patients.”